Hakim Morsli, MD
Cardiovascular Disease · Sarasota, FLNPI 1023009909
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,799 of the $87,207 with a category attached, or 93.8%. Johnson & Johnson accounts for 83.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $31,393 and has fallen 97.1% since, to $921 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 185 payments — averaging $471.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$73K
- AstraZeneca$11K
- Cvrx, Inc.$357
- Novartis$294
- Abbott$247
- Biotronik Inc.$240
- plus $1K from 19 others
Across 12 payments — averaging $9264.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$101K
- Livanova USA, Inc.$5K
- Bayer$4K
- AstraZeneca$1K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$81,79994%
- Travel & lodging$4841%
- Food & beverage$4,5865%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 80 | $73,155 |
| AstraZeneca | 15 | $11,489 |
| Cvrx, Inc. | 3 | $357 |
| Novartis | 18 | $294 |
| Abbott | 4 | $247 |
| Biotronik Inc. | 4 | $240 |
| Amgen | 12 | $219 |
| Edwards Lifesciences | 3 | $177 |
| Pfizer | 10 | $167 |
| Merck | 7 | $154 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $109 |
| Boehringer Ingelheim | 5 | $96 |
| Alnylam Pharmaceuticals Inc. | 3 | $75 |
| Impulse Dynamics (USA) Inc. | 1 | $70 |
| Philips North America LLC | 2 | $66 |
| Boston Scientific | 2 | $60 |
| Scpharmaceuticals Inc. | 2 | $41 |
| Altathera Pharmaceuticals LLC | 1 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $33 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$72,395
- FARXIGA$11,475
- Barostim Neo System$335
- BioMonitor$132
- CARDIOMEMS$124
How this compares
$87,207 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 82 | $2,102,787 |
| EliquisApixaban | 997 | $1,273,772 |
| XareltoRivaroxaban | 779 | $1,041,087 |
| EntrestoSacubitril/Valsartan | 313 | $412,472 |
| Repatha SureclickEvolocumab | 142 | $184,864 |
| FarxigaDapagliflozin Propanediol | 181 | $171,739 |
| MultaqDronedarone Hcl | 62 | $105,760 |
| JardianceEmpagliflozin | 54 | $68,158 |
| BrilintaTicagrelor | 41 | $43,152 |
| Praluent PenAlirocumab | 23 | $27,117 |
| Repatha PushtronexEvolocumab | 24 | $21,008 |
| Repatha SyringeEvolocumab | 29 | $20,786 |
| Metoprolol Succinate | 1,448 | $18,880 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 20 | $13,746 |
| Atorvastatin Calcium | 1,565 | $11,464 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $167 | $3,376,5601,079 claims |
| Johnson & JohnsonXarelto | $73,155 | $1,041,087779 claims |
| NovartisEntresto | $294 | $412,472313 claims |
| AstraZenecaFarxiga, Brilinta | $11,489 | $214,891222 claims |
| Sanofi-aventis U.S. LLCMultaq | $25 | $105,76062 claims |
| Boehringer IngelheimJardiance | $96 | $68,15854 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Sarasota
- Manfouz El ShahawySarasota$116K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.